APA (7th ed.) Citation

Florian Ottenlinger, Christoph Alexander Mayer, Nerea Ferreirós, Yannick Schreiber, Anja Schwiebs, Katrin Schmidt, . . . Heinfried H. Radeke. (2016). Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Florian Ottenlinger, Christoph Alexander Mayer, Nerea Ferreirós, Yannick Schreiber, Anja Schwiebs, Katrin Schmidt, Hanns Ackermann, Josef Pfeilschifter, and Heinfried H. Radeke. Interferon-beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab. Frontiers Media S.A., 2016.

MLA (9th ed.) Citation

Florian Ottenlinger, et al. Interferon-beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab. Frontiers Media S.A., 2016.